3D Medicines, Inc.

As of December 31, 2024, 3D Medicines, Inc. carries a market capitalization of 754.42M, placing it among publicly traded companies globally. Its enterprise value stands at 25.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2024, 3D Medicines, Inc. has 244.94M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, 3D Medicines, Inc. maintains a current ratio of 2.02, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 22, 2026, 3D Medicines, Inc.'s stock has declined approximately 59.34% over the past 52 weeks. The 50-day moving average sits at 2.53, while the 200-day moving average is 3.36.

As of December 31, 2024, 3D Medicines, Inc. holds 894.98M in cash and equivalents against 252.88M in total debt, resulting in a net debt position of -237.56M. Total book value stands at 835.48M, with working capital of 532.07M providing operational flexibility.